Alkermes plc ALKS announced the initiation of the phase II Vibrance-2 study, evaluating its novel, investigational, oral orexin 2 receptor agonist ALKS 2680 in adults with narcolepsy type 2 (NT2). The ...

̶ Data From Narcolepsy Type 2 Cohort of ALKS 2680 Phase 1b Study to be Presented in Oral Presentation ̶ ̶ Data From Idiopathic Hypersomnia Cohort of ALKS 2680 Phase 1b Study Accepted for Poster ...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40th annual meeting of the Associated ...

— Orexin 2 Receptor Agonist ALKS 2680 Demonstrated Clinically Meaningful and Statistically Significant Improvements from Baseline in Mean Sleep Latency Compared to Placebo at All Doses Tested in Both ...

Veterans with narcolepsy type 1 or other narcolepsy face elevated risk for all-cause mortality compared with a general sleep clinic cohort.

Narcolepsy was linked to high blood pressure, hyperlipidemia, and diabetes on top of outright cardiovascular disease events in a retrospective cohort study. Notably, patients with narcolepsy started ...

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo ...